Botulinum Toxin Therapy

Section II - Botulinum Toxin Therapy

Published online by Cambridge University Press: 31 May 2018

Edited by

Dirk Dressler ,

Eckart Altenmüller and

Joachim K. Krauss

Show author details

Dirk Dressler: Affiliation:
Hannover Medical School
Eckart Altenmüller: Affiliation:
Hochschule für Musik, Theater und Medien, Hannover
Joachim K. Krauss: Affiliation:
Hannover Medical School

Book contents

Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Type: Chapter
Information: Treatment of Dystonia , pp. 97 - 192

DOI: https://doi.org/10.1017/9781316459324 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Careta, MF, Delgado, L and Patriota, R, 2015. Report of allergic reaction after application of botulinum toxin. Aesthet Surg J. 35: NP102–NP105.CrossRef Google Scholar PubMed

Eisele, KH, Fink, K, Vey, M and Taylor, HV, 2011. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon. 57: 555–565.Google Scholar

Elston, JS and Russell, RW, 1985. Effect of treatment with botulinum toxin on neurogenic blepharospasm. Br Med J (Clin Res Ed). 290: 1857–1859.CrossRef Google Scholar PubMed

Fujinaga, Y, Sugawara, Y and Matsumura, T, 2013. Uptake of botulinum neurotoxin in the intestine. Curr Top Microbiol Immunol. 364: 45–59.Google Scholar PubMed

Glogau, R, Blitzer, A, Brandt, F, Kane, M, Monheit, GD and Waugh, JM, 2012. Results of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a botulinum toxin type A topical gel for the treatment of moderate-to-severe lateral canthal lines. J Drugs Dermatol. 11: 38–45.Google Scholar

Kamin, W, Staubach, P, Klar-Hlawatsch, B and Knuf, M, 2006. Anaphylaxis after vaccination due to hypersensitivity to gelatin. Klin Padiatr. 218: 92–94.CrossRef Google Scholar PubMed

Kim, BJ, Kwon, HH, Park, SY, et al., 2014. Double-blind, randomized non-inferiority trial of a novel botulinum toxin A processed from the strain CBFC26, compared with onabotulinumtoxin A in the treatment of glabellar lines. J Eur Acad Dermatol Venereol. 28: 1761–1767.CrossRef Google Scholar PubMed

Masuyer, G, Chaddock, JA, Foster, KA and Acharya, KR, 2014. Engineered botulinum neurotoxins as new therapeutics. Annu Rev Pharmacol Toxicol. 54: 27–51.CrossRef Google Scholar PubMed

Pickett, A, 2013. Historical aspects of botulinum toxin used clinically: part I – is that the right serotype? The Botulinum J. 2: 176.CrossRef Google Scholar

Pickett, A, 2015. Historical aspects of botulinum toxin used clinically: part II: overcoming resistance. The Botulinum J. doi: https://doi.org/10.1504/TBJ.2015.078134.Google Scholar

Scott, AB, Rosenbaum, A and Collins, CC, 1973. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 12: 924–927.Google Scholar PubMed

References

Antonucci, F, Rossi, C, Gianfranceschi, L, Rossetto, O, Caleo, M (2008) Long-distance retrograde effects of botulinum neurotoxin. A J Neurosci 28:3689–96.Google Scholar PubMed

Binz, T (2013) Clostridial neurotoxin light chains: devices for SNARE cleavage mediated blockade of neurotransmission. Curr Top Microbiol Immunol 364:139–157.Google Scholar

Binz, T, Rummel, A (2009) Cell entry strategy of clostridial neurotoxins. J Neurochem 109:1584–1595.CrossRef Google Scholar PubMed

Colasante, C, Rossetto, O, Morbiato, L, Pirazzini, M, Molgó, J, Montecucco, C (2013) Botulinum neurotoxin type A is internalized and translocated from small synaptic vesicles at the neuromuscular junction. Mol Neurobiol 48:120–127.CrossRef Google Scholar PubMed

Eisele, KH, Fink, K, Vey, M, Taylor, HV (2011) Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon 57:555–565.CrossRef Google Scholar PubMed

Eleopra, R, Tugnoli, V, Quatrale, R, Rossetto, O, Montecucco, C (2004) Different types of botulinum toxin in humans. Mov Disord 8:S53–S59.CrossRef Google Scholar

Fischer, A, Montal, M (2007) Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J Biol Chem 282: 29604–29611.CrossRef Google Scholar PubMed

Gu, S, Rumpel, S, Zhou, J, Strotmeier, J, Bigalke, H, Perry, K, Shoemaker, CB, Rummel, A, Jin, R (2012) Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science 335:977–981.CrossRef Google Scholar

Hill, KK, Smith, TJ (2013) Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes. Curr Top Microbiol Immunol 364:1–20.Google Scholar PubMed

Hughes, R, Whaler, BC (1962) Influence of nerve-ending activity and of drugs on the rate of paralysis of rat diaphragm preparations by Cl. botulinum type A toxin. J Physiol 160:221–233.Google Scholar

Johnson, EA, Montecucco, C (2008) Botulism. Handb Clin Neurol 91:333–368.Google Scholar

Lacy, DB, Tepp, W, Cohen, A, DasGupta, BR, Stevens, RC (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5:898–902.CrossRef Google Scholar PubMed

Lee, K, Gu, S, Jin, L, Le, TT, Cheng, LW, Strotmeier, J, Kruel, AM, Yao, G, Perry, K, Rummel, A, Jin, R (2013) Structure of a bimodular botulinum neurotoxin complex provides insights into its oral toxicity. PLoS Pathog 9:e1003690.CrossRef Google Scholar PubMed

Masuyer, G, Chaddock, JA, Foster, KA, Acharya, KR (2014) Engineered botulinum neurotoxins as new therapeutics. Annu Rev Pharmacol Toxicol 54: 27–51.CrossRef Google Scholar PubMed

Mazzocchio, R, Caleo, M (2015) More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system. Neuroscientist 21:44–61.CrossRef Google Scholar

Montal, M (2010) Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem 79:591–617.Google Scholar

Montecucco, C (1986) How do tetanus and botulinum toxins bind to neuronal membranes? Trends Biochem Sci 11:314–317.CrossRef Google Scholar

Montecucco, C, Rasotto, MB (2015) On botulinum neurotoxin variability. MBio 6:e02131-14.CrossRef Google Scholar PubMed

Pantano, S, Montecucco, C (2014) The blockade of the neurotransmitter release apparatus by botulinum neurotoxins. Cell Mol Life Sci 71:793–811.CrossRef Google Scholar PubMed

Pellett, S, Tepp, WH, Whitemarsh, RC, Bradshaw, M, Johnson, EA (2015) In vivo onset and duration of action varies for botulinum neurotoxin A subtypes 1–5. Toxicon 107(Pt A):37–42.Google Scholar

Pirazzini, M, Bordin, F, Rossetto, O, Shone, CC, Binz, T, Montecucco, C (2013) The thioredoxin reductase–thioredoxin system is involved in the entry of tetanus and botulinum neurotoxins in the cytosol of nerve terminals. FEBS Lett 587:150–155.CrossRef Google Scholar PubMed

Pirazzini, M, Azarnia Tehran, D, Zanetti, G, Megighian, A, Scorzeto, M, Fillo, S, Shone, CC, Binz, T, Rossetto, O, Lista, F, Montecucco, C (2014) Thioredoxin and its reductase are present on synaptic vesicles, and their inhibition prevents the paralysis induced by botulinum neurotoxins. Cell Rep 8:1870–1878.CrossRef Google Scholar PubMed

Pirazzini, M, Azarnia Tehran, D, Leka, O, Zanetti, G, Rossetto, O, Montecucco, C (2016) On the translocation of botulinum and tetanus neurotoxins across the membrane of acidic intracellular compartments. Biochim Biophys Acta 1858:467–474.Google Scholar

Restani, L, Giribaldi, F, Manich, M, Bercsenyi, K, Menendez, G, Rossetto, O, Caleo, M, Schiavo, G (2012) Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLoS Pathog 8:e1003087.Google Scholar

Rossetto, O, Pirazzini, M, Montecucco, C (2014) Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol 12:535–549.Google Scholar

Rossetto, O, Pirazzini, M, Montecucco, C (2015) Current gaps in basic science knowledge of botulinum neurotoxin biological actions. Toxicon 107(Pt A):59–63.CrossRef Google Scholar PubMed

Rummel, A (2013) Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity. Curr Top Microbiol Immunol 364:61–90.Google Scholar

Simpson, L (2013) The life history of a botulinum toxin molecule. Toxicon 68:40–59.CrossRef Google Scholar PubMed

Smith, LD, Sugiyama, H (1988) Botulism: The Organism, its Toxins, the Disease. Springfield, IL: C.C. Thomas Publisher.Google Scholar

References

Aoki, KR (2005). Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicol 26:785–793.CrossRef Google Scholar PubMed

Byrnes, ML, Thickbroom, GW, Wilson, SA, Sacco, P, Shipman, JM, Stell, R (1998). The corticomotor representation of upper limb muscles in writer’s cramp and changes following botulinum toxin injection. Brain 121:977–988.Google Scholar

Caleo, M, Antonucci, F, Restani, L, Mazzocchio, R (2009). A re-appraisal of the central effects of botulinum toxin type A: by what mechanism? J Neurochem 109: 15–24.Google Scholar

Ce, P (2000). Central effects of botulinum toxin: study of brainstem auditory evoked potentials. Eur J Neurol 7: 747.CrossRef Google Scholar PubMed

Ceballos-Baumann, AO, Sheean, G, Passingham, RE, Marsden, CD, Brooks, DJ (1997). Botulinum toxin does not reverse the cortical dysfunction associated with writer’s cramp: a PET study. Brain 120:571–582.Google Scholar

Conte, A, Fabbrini, G, Belvisi, D, Marsili, K, Di Stasio, F, Berardelli, A (2010). Electrical activation of the orbicularis oculi muscle does not increase the effectiveness of botulinum toxin type A in patients with blepharospasm. Eur J Neurol 17:449–455.CrossRef Google Scholar

Eleopra, R, Tugnoli, V, De Grandis, D, Montecucco, C (1998). Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 256: 135–138.CrossRef Google Scholar

Fascarelli, F, Di Rosa, G, Bisozzi, E, Castelli, E, Santilli, V (2011). Neurophysiological changes induced by the botulinum toxin type A injection in children with cerebral palsy. Eur J Paediat Neurol 15: 59–64.CrossRef Google Scholar

Habermann, E (1974). ¹²⁵I labeled neurotoxin from Clostridium botulinum A: preparation, binding to synaptomoses and ascent to spinal cord. Naunyn Schmiedebergs Arch Pharmacol 281: 47–56.Google Scholar

Hagenah, R, Bebecke, R, Wiegand, H (1977). Effect of type A botulinum toxin on the cholinergic transmission at the spinal Renshaw cells and on the inhibitory action at Ia inhibitory interneurons. Arch Pharmal 299: 267–272.Google Scholar

Hamjian, JA, Walker, F (1994). Serial neurophysiological studies of intramuscular botulinum-A toxins in human. Muscle Nerve 17: 1385–1392.CrossRef Google Scholar

Kaji, R, Rosako, Y, Suyama, K, Maeda, T, Uechi, Y, Iwasaki, M (2010). Botulinum toxin type A in post-stroke upper limb spasticity. Curr Med Res Opin 26:1983–1992.Google Scholar

Kanovský, P, Rosales, RL (2011). Debunking the pathophysiological puzzle of dystonia: with special reference to botulinum toxin therapy. Parkinsonism Relat Disord 17: S11–S14.Google Scholar

Kim, DY, Oh, BM, Paik, NJ (2006). Central effect of botulinum toxin A in humans. Int J Neurosci 116(6): 667–680.CrossRef Google Scholar PubMed

Kojovic, M, Caronni, A, Bologna, M, Bhatia, K, Rothwell, J, Edwards, M (2011). Botulinum toxin injections reduce associative plasticity in patients with primary dystonia. Movement Disord 26(7): 1282–1289.Google Scholar

Naumann, M, Reiners, R (1997). Long-latency reflexes of hand muscles in idiopathic focal dystonia and their modification by botulinum toxin. Brain 120: 409–416.Google Scholar

Palomar, F, Mir, P (2012). Neurophysiological changes after intramuscular injection of botulinum toxin. Clinic Neurophysiol 123: 54–60.CrossRef Google Scholar PubMed

Picelli, A, Lobba, D, Midiri, A, Prandi, P, Melotti, C, Baldessarelli, S, Smania, N (2014). Botulinum toxin injection into the forearm muscles for wrist and fingers spastic overactivity in adults with chronic stroke: a randomized controlled trial comparing three injection techniques. Clin Rehabil 28(3): 232–242.Google Scholar

Pickett, A, Rosales, RL (2011). New trends in the science of botulinum toxin-A as applied in dystonia. Int J Neurosci 121: 22–34.Google Scholar

Pierrot-Deseilligny, E, Burke, D. (2005). The Circuitry of the Human Spinal Cord: Its Role in Motor Control and Movement Disorders. Cambridge: Cambridge University Press.Google Scholar

Priori, A, Berardelli, A, Mercuri, B, Manfredi, M (1995). Physiological effects produced by botulinum toxin treatment of upper limb dystonia: changes in reciprocal inhibition between forearm muscles. Brain 118:801–807.Google Scholar

Rosales, RL (2012). Dystonia, spasticity and botulinum toxin therapy: rationale, evidences and clinical context. In: Rosales, RL (Ed.), Dystonia: The Many Facets. Croatia: Intech Open Access Publishers.Google Scholar

Rosales, RL, Dressler, D (2010). On muscle spindles, dystonia and botulinum toxin. Eur J Neurol 17 (Suppl. 1): 71–80.Google Scholar

Rosales, RL, Arimura, K, Takenaga, S, Osame, M (1996). Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 19: 488–496.Google Scholar

Rosales, RL, Dressler, D, Bigalke, H (2006). Pharmacologic differences between botulinum toxins. Eur J Neurol 13: 2–10.Google Scholar

Rosales, RL, Delos Santos, MM, Ng, AR, Teleg, R, Dantes, M, Lee, LV, Fernandez, HH (2011a). The broadening application of chemodenervation in X-linked dystonia-parkinsonism (part I): muscle afferent block versus botulinum toxin-A in cervical and limb dystonias. Int J Neurosci 121: 35–43.Google Scholar

Rosales, RL, Kanovsky, P, Fernandez, HH (2011b). What’s the ‘catch’ in upper-limb post-stroke spasticity: expanding the role of botulinum toxin applications. Parkinsonism Relat Disord 17: S3–S10.CrossRef Google Scholar PubMed

Rosales, RL, Kong, KH, Goh, KJ, Kumthornthip, W, Mok, VCT, Delgado-De Los Santos, MM, Chua, KSG, Abdullah, SJF, Zakine, B, Maisonob, P, Magis, A, Wong, KSL (2012). Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: a randomized controlled trial. Neurorehabil Neural Repair 26(7): 812–821.Google Scholar

Senkarova, Z, Hlustik, P, Otruba, P, Herzig, R, Kanovsky, P (2010). Modulation of cortical activity in patients suffering from upper arm spasticity following stroke and treated with botulinum toxin A: an fMRI study. J Neuroimaging 20: 9–15.CrossRef Google Scholar PubMed

Ward, SR, Lieber, RL (2009). Biological and mechanical pathologies in spastic skeletal muscle: the functional implications of therapeutic toxins. In: Jankovic, J (Ed.), Botulinum Toxin: Therapeutic Clinical Practice and Science. Philadelphia, PA: Saunders.Google Scholar

Wohlfarth, K, Schubert, M, Rothe, B, Elek, J, Dengler, R (2001). Remote F-wave changes after local botulinum toxin application. Clin Neurophysiol 112: 636–640.Google Scholar

Yamada, N, Kakuda, W, Kondo, T, Mitani, S, Shimizu, M, Abo, M (2014). Local muscle injection of botulinum toxin type A synergistically improves the beneficial effects of repetitive transcranial magnetic stimulation and intensive occupational therapy in post-stroke patients with spastic upper limb hemiparesis. Eur Neurol 72: 290–298.Google Scholar

Zeuner, KE, Knutzen, A, Al-Ali, A, Hallett, M, Deuschl, G, Bergmann, TO (2010). Associative stimulation of the supraorbital nerve fails to induce timing-specific plasticity in the human blink reflex. PLoS One 5:13602–13614.Google Scholar

References

Antonucci, F, Rossi, C, Gianfranceschi, L, Rossetto, O, Caleo, M (2008). Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 28:3689–3696.CrossRef Google Scholar PubMed

Aymard, C, Giboin, LS, Lackmy-Vallee, A, Marchand-Pauvert, V (2013). Spinal plasticity in stroke patients after botulinum neurotoxin A injection in ankle plantar flexors. Physiol Rep 1:e00173.Google Scholar

Bomba-Warczak, E, Vevea, JD, Brittain, JM, Figueroa-Bernier, A, Tepp, WH, Johnson, EA, Yeh, FL, Chapman, ER (2016). Interneuronal transfer and distal action of tetanus toxin and botulinum neurotoxins A and D in central neurons. Cell Rep 16:1974–1987.CrossRef Google Scholar

Brink, EE, Suzuki, I (1987). Recurrent inhibitory connexions among neck motoneurones in the cat. J Physiol 383:301–326.Google Scholar

Giladi, N (1997). The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neurol Sci 152:132–135.CrossRef Google Scholar PubMed

Hallett, M (2011). Neurophysiology of dystonia: the role of inhibition. Neurobiol Dis 42:177–184.Google Scholar

Koizumi, H, Goto, S, Okita, S, Morigaki, R, Akaike, N, Torii, Y, Harakawa, T, Ginnaga, A, Kaji, R (2014). Spinal central effects of peripherally applied botulinum neurotoxin A in comparison between its subtypes A1 and A2. Front Neurol 5:98.CrossRef Google Scholar PubMed

Marchand-Pauvert, V, Iglesias, C (2008). Properties of human spinal interneurones: normal and dystonic control. J Physiol 586:1247–1256.Google Scholar

Marchand-Pauvert, V, Aymard, C, Giboin, LS, Dominici, F, Rossi, A, Mazzocchio, R (2013). Beyond muscular effects: depression of spinal recurrent inhibition after botulinum neurotoxin A. J Physiol 591:1017–1029.CrossRef Google Scholar PubMed

Matak, I, Lackovic, Z (2014). Botulinum toxin A, brain and pain. Prog Neurobiol 119–120:39–59.Google Scholar

Matsuo, K, Ban, R, Ban, M, Yuzuriha, S (2014). Trigeminal proprioception evoked by strong stretching of the mechanoreceptors in Muller’s muscle induces reflex contraction of the orbital orbicularis oculi slow-twitch muscle fibers. Eplasty 14:e30.Google Scholar PubMed

Mazzocchio, R, Caleo, M (2015). More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system. Neuroscientist 21:44–61.Google Scholar

Moreno-Lopez, B, Pastor, AM, de la Cruz, RR, Delgado-Garcia, JM (1997). Dose-dependent, central effects of botulinum neurotoxin type A: a pilot study in the alert behaving cat. Neurology 48:456–464.Google Scholar

Pastor, AM, Moreno-Lopez, B, De La Cruz, RR, Delgado-Garcia, JM (1997). Effects of botulinum neurotoxin type A on abducens motoneurons in the cat: ultrastructural and synaptic alterations. Neuroscience 81:457–478.Google Scholar

Ramachandran, R, Lam, C, Yaksh, TL (2015). Botulinum toxin in migraine: role of transport in trigemino-somatic and trigemino-vascular afferents. Neurobiol Dis 79:111–122.Google Scholar

Restani, L, Giribaldi, F, Manich, M, Bercsenyi, K, Menendez, G, Rossetto, O, Caleo, M, Schiavo, G (2012a). Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLoS Pathog 8:e1003087.Google Scholar

Restani, L, Novelli, E, Bottari, D, Leone, P, Barone, I, Galli-Resta, L, Strettoi, E, Caleo, M (2012b). Botulinum neurotoxin A impairs neurotransmission following retrograde transynaptic transport. Traffic 13:1083–1089.Google Scholar

Rossetto, O, Pirazzini, M, Montecucco, C (2015). Current gaps in basic science knowledge of botulinum neurotoxin biological actions. Toxicon 107(Pt A):59–63.Google Scholar

Salinas, S, Schiavo, G, Kremer, EJ (2010). A hitchhiker’s guide to the nervous system: the complex journey of viruses and toxins. Nat Rev Microbiol 8:645–655.Google Scholar

Valls-Sole, J, Tolosa, ES, Ribera, G (1991). Neurophysiological observations on the effects of botulinum toxin treatment in patients with dystonic blepharospasm. J Neurol Neurosurg Psychiatry 54:310–313.Google Scholar

Verderio, C, Pozzi, D, Pravettoni, E, Inverardi, F, Schenk, U, Coco, S, Proux-Gillardeaux, V, Galli, T, Rossetto, O, Frassoni, C, Matteoli, M (2004). SNAP-25 modulation of calcium dynamics underlies differences in GABAergic and glutamatergic responsiveness to depolarization. Neuron 41:599–610.Google Scholar

Wang, T, Martin, S, Papadopulos, A, Harper, CB, Mavlyutov, TA, Niranjan, D, Glass, NR, Cooper-White, JJ, Sibarita, JB, Choquet, D, Davletov, B, Meunier, FA (2015). Control of autophagosome axonal retrograde flux by presynaptic activity unveiled using botulinum neurotoxin type A. J Neurosci 35:6179–6194.Google Scholar

References

Agafonova, NV, Khasanova, DR (2014) [The use of different doses of botulotoxin A in the treatment of early arm poststroke spasticity]. [Article in Russian] Zh Nevrol Psikhiatr Im S S Korsakova 114: 68–71.Google Scholar

Aoki, R (2002) Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon 40: 923–928.CrossRef Google Scholar

Arnouk, R, Suzuki Bellucci, C, Benatuil Stull, R, de Bessa, J, Malave, C, Gomes, C (2012) Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: randomized study comparing two doses. Sci World J 2012: 463574.Google Scholar PubMed

Bach-Rojecky, L, Lacković, Z (2005) Antinociceptive effect of botulinum toxin type A in rat model of carrageenan and capsaicin induced pain. Croat Med J 46: 201–208.Google Scholar PubMed

Bach-Rojecky, L, Lacković, Z (2009) Central origin of the antinociceptive action of botulinum toxin type A. Pharmacol Biochem Behav 94(2): 234–238. doi: 10.1016/j.pbb.2009.08.012.Google Scholar

Basciani, M, DiRienzo, F, Fontana, A, Copetti, M, Pellegrini, F, Intiso, D (2011) Botulinum toxin type B for sialorrhoea in children with cerebral palsy: a randomized trial comparing three doses. Dev Med Child Neurol 53: 559–564.CrossRef Google Scholar PubMed

Bittencourt da Silva, L, Karshenas, A, Bach, F, Rasmussen, S, Arendt-Nielsen, L, Gazerani, P (2014) Blockade of glutamate release by botulinum neurotoxin type A in humans: a dermal microdialysis study. Pain Res Manag 19: 126–132.CrossRef Google Scholar PubMed

Camargo, C, Cattai, L, Teive, H (2015) Pain relief in cervical dystonia with botulinum toxin treatment. Toxins (Basel) 7: 2321–2335.Google Scholar

Cui, M, Khanijou, S, Rubino, J, Aoki, K (2004) Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107: 125–133.Google Scholar

Currà, A, Berardelli, A (2009) Do the unintended actions of botulinum toxin at distant sites have clinical implications? Neurology 72:1095–1099.Google Scholar

Dodick, D, Turkel, C, DeGryse, R, Aurora, S, Silberstein, S, Lipton, R, Diener, H, Brin, MF, PREEMPT Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind randomized placebo-controlled phases of the PREEMPT clinical program. Headache 50: 921–936.Google Scholar

Dressler, D, Adib Saberi, F (2013) Towards a dose optimisation of botulinum toxin therapy for axillary hyperhidrosis: comparison of different Botox doses. J Neural Transm 120: 1565–1567.CrossRef Google Scholar PubMed

Dressler, D, Benecke, R (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 49: 34–38.CrossRef Google Scholar PubMed

Dressler, D, Eleopra, R (2006) Clinical use of non-A botulinum toxins: botulinum toxin type B. Neurotox Res 9: 121–125.Google Scholar

Fedorowicz, Z, van Zuuren, E, Schoones, J (2013) Botulinum toxin for masseter hypertrophy. Cochrane Database of Systematic Reviews 9(9): CD007510.Google Scholar

Göbel, H, Heinze, A, Reiche, G, Hefter, H, Benecke, R, Dysport Myofascial Pain Study Group (2006) Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study. Pain 125: 82–88.Google Scholar

Hu, Y, Guan, X, Fan, L, Li, M, Liao, Y, Nie, Z, Jin, L (2013) Therapeutic efficacy and safety of botulinum toxin type A in trigeminal neuralgia: a systematic review. J Headache Pain 14: 72.Google Scholar

Intiso, D, Basciani, M, Santamato, A, Intiso, M, Di Rienzo, F (2015) Botulinum toxin type A for the treatment of neuropathic pain in neuro-rehabilitation. Toxins 7: 2454–2480.Google Scholar

Kollewe, K, Mohammadi, B, Köhler, S, Pickenbrock, H, Dengler, R, Dressler, D (2015) Blepharospasm: long-term treatment with either Botox^® Xeomin^® or Dysport^®. J Neural Transm 122: 427–431.CrossRef Google Scholar PubMed

Langevin, P, Peloso, PM, Lowcock, J, Nolan, M, Weber, J, Gross, A, Roberts, J, Goldsmith, CH, Graham, N, Burnie, SJ, Haines, T (2011) Botulinum toxin for subacute/chronic neck pain. Cochrane Database Syst Rev 7: CD008626.Google Scholar

Marino, MJ, Terashima, T, Steinauer, JJ, Eddinger, KA, Yaksh, TL, Xu, Q (2014) Botulinum toxin B in the sensory afferent: transmitter release spinal activation and pain behavior. Pain 155: 674–684.Google Scholar

Matak, I, Lacković, Z (2014) Botulinum toxin A brain and pain. Prog Neurobiol 119–120: 39–59.Google Scholar

Matak, I, Lacković, Z (2015) Botulinum neurotoxin type A: actions beyond SNAP-25. Toxicology 335: 79–84.Google Scholar

Mense, S (2004) Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol 251(Suppl. 1): 1–7.Google Scholar

Relja, M, Klepac, N (2002) Different doses of botulinum toxin A and pain responsiveness in cervical dystonia. Neurology 58: A474.Google Scholar

Relja, M, Poole, AC, Schoenen, J, Pascual, J, Lei, X, Thompson, C, European BoNTA Headache Study Group (2007) A multicentre double-blind randomized placebo-controlled parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 27: 492–503.Google Scholar

Singh, JA, Fitzgerald, PM (2011) Botulinum toxin for shoulder pain: a Cochrane systematic review. J Rheumatol 38(3): 409–418.Google Scholar

Soares, A, Andriolo, RB, Atallah, AN, da Silva, EM (2012) Botulinum toxin for myofascial pain syndromes in adults. Cochrane Database Syst Rev 4: CD007533.Google Scholar

Tsui, JK, Eisen, A, Stoessl, AJ, Calne, S, Calne, DB (1986) Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 2: 245–247.Google Scholar

Waseem, Z, Boulias, C, Gordon, A, Ismail, F, Sheean, G, Furlan, AD (2010) Botulinum toxin injections for low-back pain and sciatica. Cochrane Database Syst Rev 1: CD008257.Google Scholar

Winocour, S, Murad, MH, Bidgoli-Moghaddam, M, Jacobson, SR, Bite, U, Saint-Cyr, M, Tran, NV, Lemaine, V (2014) Systematic review of the use of botulinum toxin type A with subpectoral breast implants. J Plast Reconstr Aesthet Surg 67: 34–41.Google Scholar

Wu, T, Fu, Y, Song, HX, Ye, Y, Dong, Y, Li, JH (2015) Effectiveness of botulinum toxin for shoulder pain treatment: a systematic review and meta-analysis. Arch Phys Med Rehabil 16(15).Google Scholar

Zhang, H, Lian, Y, Ma, Y, Chen, Y, He, C, Xie, N, Wu, C (2014) Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized double-blind placebo-controlled trial. J Headache Pain 15: 65.CrossRef Google Scholar PubMed

References

Borodic, G, Johnson, EA, Goodnough, MC, Schantz, EJ (1996) Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 46: 26–29.Google Scholar

Brashear, A (2001) Botulinum toxin type B: a new injectable treatment for cervical dystonia. Expert Opin Invest Drugs 10: 2191–2199.CrossRef Google Scholar PubMed

Burgen, ASV, Dickens, F, Zatman, LF (1949) The action of botulinum toxin on the neuro-muscular junction. J Physiol 109: 10–24.Google Scholar

DasGupta, BR (1989) The structure of botulinum neurotoxin. In: Simpson, LL, ed., Botulinum Neurotoxin and Tetanus Toxin. San Diego, ca, Academic Press, pp. 53–67.Google Scholar

Drachman, DB (1971) Botulinum toxin as a tool for research on the nervous system. In: Simpson, LL, ed., Neuropoisons: Their Pathophysiological Actions. Vol. 1. Poisons of Animal Origin. New York, Plenum Press, pp. 325–347.CrossRef Google Scholar

Frevert, J (2015) Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D 15: 1–9.Google Scholar

Geigert, J (2013) The Challenge of CMC Regulatory Compliance for Biopharmaceuticals. New York, Springer-Verlag.CrossRef Google Scholar

Hambleton, P, Capel, B, Bailey, N, Heron, N, Crooks, A, Melling, J, Tse, C-K, Dolly, JO (1981) Production, purification and toxoiding of Clostridium botulinum type A toxin. In: Lewis, GE, ed., Biomedical Aspects of Botulism. New York, Academic Press, pp. 247–260.Google Scholar

Hatheway, CL, Johnson, EA (1998) Clostridium: the spore-bearing anaerobes. In: Collier, L, Balows, A, Sussman, M, eds, Topley and Wilson’s Microbiology and Microbial Infections, ninth edition, Vol. 2: Systematic Bacteriology. London, Arnold, pp. 731–782.Google Scholar

Hill, KK, Xie, G, Foley, BT, Smith, TJ (2015) Genetic diversity within the botulinum neurotoxin-producing bacteria and their neurotoxins. Toxicon 107 (Pt A): 2–8.Google Scholar

Hutson, RA, Zhou, Y, Johnson, EA, Sugiyama, H, Hatheway, CL (1996) Genetic characterization of Clostridium botulinum type A containing silent B neurotoxin gene sequences. J Biol Chem 271: 10786–10792.Google Scholar

Johnson, EA (1999) Clostridial toxins as therapeutic agents: benefits of nature’s most toxic proteins. Ann Rev Microbiol 53: 551–575.Google Scholar

Malizio, CJ, Goodnough, MC, Johnson, EA (2000) Purification of Clostridium botulinum type A neurotoxin. In: Holst, O, ed., Bacterial Toxins: Methods and Protocols. New Jersey, Humana Press.Google Scholar

Panjwani, N, O’Keefe, RO, Pickett, A (2008) Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. The Botulinum J 1: 153–166.CrossRef Google Scholar

Pickett, A (2014) Botulinum toxin as a clinical product: manufacture and pharmacology. In: Foster, KA, ed., Clinical Applications of Botulinum Neurotoxin. New York, Springer, pp. 7–49.CrossRef Google Scholar

Rossetto, O, Pirazzini, M, Montecucco, C (2014) Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol 12: 535–549.Google Scholar

Sakaguchi, G (1982) Clostridium botulinum toxins. Pharmacol Ther 19: 165–194.Google Scholar

Schantz, EJ, Johnson, EA (1992) Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 56: 80–92.Google Scholar

Scott, AB (1981) Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophtthalmol Soc 79: 734–770.Google Scholar PubMed

Scott, AB (1989) Clostridial toxins as therapeutic agents. In: Simpson, LL, ed., Botulinum Neurotoxin and Tetanus Toxin. San Diego, CA, Academic Press, pp. 399–412.Google Scholar

Scott, AB, Rosenbaum, A, Collins, CC (1973) Pharmacologic weakening of extraocular muscles. Invest Opthamol 12: 924–927.Google Scholar

Sugiyama, H (1980) Clostridium botulinum neurotoxin. Microbiol Rev 44: 419–448.CrossRef Google Scholar PubMed

Wortzman, MS, Pickett, A (2009) The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use. Aesthet Surg J 29: S34–S42.Google Scholar

References

Antonucci, F, Rossi, C, Gianfranceschi, L, Rossetto, O, Caleo, M (2008) Long-distance retrograde effects of botulinum neurotoxin. A J Neurosci 28:3689–3696.Google Scholar

Aurora, SK, Dodick, DW, Diener, HC, DeGryse, RE, Turkel, CC, Lipton, RB, Silberstein, SD (2014) OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol Scand 129:61–70.CrossRef Google Scholar PubMed

Beard, M (2014) Translocation, entry into the cell. In: Foster, KA (ed.) Molecular Aspects of Botulinum Neurotoxin. New York: Springer; pp151–170.Google Scholar

Brin, MF, Dressler, D, Aoki, R (2004) Pharmacology of botulinum toxin therapy. In: Jankovic, J, Comella, C, Brin, MF (eds) Dystonia: Etiology, Clinical Features, and Treatment. Philadelphia, PA: Lippincott Williams & Wilkins; pp93–112.Google Scholar

Brin, MF, James, C, Maltman, J (2014) Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics 8:227–241.Google Scholar

de Paiva, A, Meunier, FA, Molgo, J, Aoki, KR, Dolly, JO (1999) Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 96:3200–3205.CrossRef Google Scholar PubMed

Dressler, D, Benecke, R (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 49:34–38.Google Scholar

Dressler, D, Rothwell, JC (2000) Electromyographic quantification of the paralysing effect of botulinum toxin. Eur Neurol 43:13–16.Google Scholar

Dressler, D, Eckert, J, Kukowski, B, Meyer, BU (1993) Somatosensorisch Evozierte Potentiale bei Schreibkrampf: Normalisierung pathologischer Befunde unter Botulinum Toxin Therapie. Z EEG EMG 24:191.Google Scholar

Dressler, D, Rothwell, JC, Bigalke, H (2000) The sternocleidomastoid test: an in-vivo assay to investigate botulinum toxin antibody formation in man. J Neurol 247:630–632.Google Scholar

Dressler, D, Adib Saberi, F, Benecke, R (2002) Botulinum toxin type B for treatment of axillar hyperhidrosis. J Neurol 249:1729–1732.CrossRef Google Scholar PubMed

Dressler, D, Saberi, FA, Kollewe, K, Schrader, C (2015) Safety aspects of incobotulinumtoxinA high-dose therapy. J Neural Transm 122:327–333.Google Scholar

Eleopra, R, Tugnoli, V, Rossetto, O, De Grandis, D, Montecucco, C (1998) Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Letts 256:135–138.Google Scholar

Fernández-Salas, E, Wang, J, Molina, Y, Nelson, JB, Jacky, BP, Aoki, KR (2012) Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay. PLoS One 7:e49516.Google Scholar

Filippi, GM, Errico, P, Santarelli, R, Bagolini, B, Manni, E (1993) Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 113:400–404.CrossRef Google Scholar PubMed

Foster, KA (2004) The analgesic potential of clostridial neurotoxin derivatives. Expert Opin Investig Drugs 13:1437–1443.CrossRef Google Scholar PubMed

Girlanda, P, Vita, G, Nicolosi, C, Milone, S, Messina, C (1992) Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry 55:844–845.CrossRef Google Scholar PubMed

Hallett, M (2015) Explanation of timing of botulinum neurotoxin effects, onset, duration, and clinical ways of influencing them. Toxicon 107:64–67.Google Scholar

Jabbari, B, Machado, DG (2014) Clinical use of botulinum neurotoxins: pain. In: Foster, KA (ed.) Clinical Applications of Botulinum Neurotoxin. New York: Springer; pp153–176.Google Scholar

Johnson, EA, Pellett, S, Whitemarsh, RCM, Tepp, WH (2013) Compositions and methods for toxigenicity testing. International Patent Application PCT/US2012/057825.Google Scholar

Kaji, R, Kohara, N, Katayama, M, Kubori, T, Mezaki, T, Shibasaki, H, Kimura, J (1995a) Muscle afferent block by intramuscular injection of lidocaine for the treatment of writer’s cramp. Muscle Nerve 18:234–235.Google Scholar

Kaji, R, Rothwell, JC, Katayama, M, Ikeda, T, Kubori, T, Kohara, N, Mezaki, T, Shibasaki, H, Kimura, J (1995b) Tonic vibration reflex and muscle afferent block in writer’s cramp. Ann Neurol 38:155–162.CrossRef Google Scholar PubMed

Keller, JE (2006) Recovery from botulinum neurotoxin poisoning in vivo. Neurosci 139:629–637.Google Scholar

Kollewe, K, Escher, C, Fathi, D, Wulff, DU, Paracka, L, Mohammadi, B, Karst, M, Dressler, D (2016) Long-term treatment of chronic migraine with onabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting. J Neural Transm 123:533–540.Google Scholar

Lange, DJ, Brin, MF, Warner, CL, Fahn, S, Lovelace, RE (1987) Distant effects of local injection of botulinum toxin. Muscle Nerve 10:552–555.Google Scholar

Mazzocchio, R, Caleo, M (2015) More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system. Neuroscientist 21:44–61.CrossRef Google Scholar

Pellizzari, R, Rossetto, O, Schiavo, G, Montecucco, C (1999) Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philos Trans R Soc Lond B Biol Sci 354:259–268.Google Scholar

Peng, L, Tepp, WH, Pitkin, RM, Johnson, EA, Stenmark, P, Dong, M (2012) Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins. J Cell Sci 125:3233–3242.Google Scholar

Rosales, RL, Arimura, K, Takenaga, S, Osame, M (1996) Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 19:488–496.3.0.CO;2-8>CrossRef Google Scholar PubMed

Rummel, A (2013) Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity. Curr Top Microbiol Immunol 364:61–90.Google Scholar

Schiavo, G, Matteoli, M, Montecucco, C (2000) Neurotoxins affecting neuroexocytosis. Physiol Rev 80:717–766.Google Scholar

Strotmeier, J, Willjes, G, Binz, T, Rummel, A (2012) Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity. FEBS Lett 586:310–313.Google Scholar

Tsai, YC, Moller, BE, Adler, M, Oyler, GA (2014) Molecular basis for persistence of botulinum neurotoxin: the role of intracellular protein degradation pathways. In: Foster, KA (ed.) Molecular Aspects of Botulinum Neurotoxin. New York: Springer; pp191–206.Google Scholar

Wohlfahrt, K, Sycha, T, Ranoux, D, Naver, H, Caird, D (2009) Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment? Curr Med Res Opin 25:1573–1584.Google Scholar

References

Biglan, AW, Gonnering, R, Lockhart, LB, Rabin, B, Fuerste, FH (1986) Absence of antibody production in patients treated with botulinum A toxin. Am J Ophthalmol 101:232–235.Google Scholar

Birklein, F, Walther, D, Bigalke, H, Winterholler, M, Erbguth, F (2002) Sudomotor testing predicts the presence of neutralizing botulinum A toxin antibodies. Ann Neurol 52:68–73.CrossRef Google Scholar PubMed

Dressler, D (2000a) Botulinum Toxin Therapy. Stuttgart: Thieme Verlag.Google Scholar

Dressler, D (2000b) Complete secondary botulinum toxin therapy failure in blepharospasm. J Neurol 247:809–810.CrossRef Google Scholar PubMed

Dressler, D (2004a) New formulation of BOTOX^®: complete antibody-induced therapy failure in hemifacial spasm. J Neurol 251:360.Google Scholar

Dressler, D (2004b) Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 19 (Suppl. 8):S92–S100.Google Scholar

Dressler, D (2012) Five-year experience with incobotulinumtoxinA (Xeomin^®): the first botulinum toxin drug free of complexing proteins. Eur J Neurol 19:385–389.Google Scholar

Dressler, D, Adib Saberi, F (2016) Immunological safety of incobotulinumtoxinA (Xeomin^®) therapy with reduced interinjection intervals. J Neural Transm 122:327–333.Google Scholar

Dressler, D, Bigalke, H (2002) Botulinum toxin antibody titres after cessation of botulinum toxin therapy. Mov Disord 17:170–173.CrossRef Google Scholar PubMed

Dressler, D, Dirnberger, G (2000) Botulinum toxin therapy: risk factors for therapy failure. Mov Disord 15 (Suppl. 2):51.Google Scholar

Dressler, D, Foster, K (in press) Pharmacology of botulinum toxins. In: Dressler, D, Altenmüller, E, Krauss, JK (eds) Treatment of Dystonia. Cambridge: Cambridge University Press.CrossRef Google Scholar

Dressler, D, Zettl, U, Bigalke, H, Benecke, R (2000a) Can intravenous immunoglobulin improve antibody mediated botulinum toxin therapy failure? Mov Disord 15:1279–1281.Google Scholar

Dressler, D, Dirnberger, G, Bhatia, K, Quinn, NP, Irmer, A, Bigalke, H, Marsden, CD (2000b) Botulinum toxin antibody testing: comparison between the mouse diaphragm bioassay and the mouse lethality bioassay. Mov Disord 15:973–976.Google Scholar

Dressler, D, Bigalke, H, Rothwell, JC (2000c) The sternocleidomastoid test: an in-vivo assay to investigate botulinum toxin antibody formation in man. J Neurol 247:630–632.Google Scholar

Dressler, D, Muenchau, A, Bhatia, KP, Quinn, NP, Bigalke, H (2002) Antibody induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses? Eur Neurol 47:118–121.Google Scholar

Dressler, D, Benecke, R, Bigalke, H (2003) Botulinum toxin type B (NeuroBloc^®) in patients with botulinum toxin type A antibody-induced therapy failure. J Neurol 250:967–969.Google Scholar

Dressler, D, Wohlfahrt, K, Meyer-Rogge, E, Wiest, L, Bigalke, H (2010) Antibody-induced failure of botulinum toxin a therapy in cosmetic indications. Dermatol Surg 36 (Suppl. 4):2182–2187.CrossRef Google Scholar PubMed

Dressler, D, Adib Saberi, F, Kollewe, K, Schrader, C (2014a) Safety aspects of incobotulinumtoxinA high dose therapy. J Neural Transm 122:327–333.Google Scholar

Dressler, D, Gessler, F, Tacik, P, Bigalke, H (2014b) An enzyme-linked immunosorbent assay for detection of botulinum toxin-antibodies. Mov Disord 29:1322–1324.Google Scholar

Dressler, D, Altenmueller, E, Bhidayasiri, R, Bohlega, S, Chana, P, Chung, TM, Frucht, S, Garcia-Ruiz, PJ, Kaelin, A, Kaji, R, Kanovsky, P, Laskawi, R, Micheli, F, Orlova, O, Relja, M, Rosales, R, Slawek, J, Timerbaeva, S, Warner, TT, Saberi, FA (2015) Strategies for treatment of dystonia. J Neural Transm (epub ahead of printing).Google Scholar

Duane, DD, Monroe, J, Morris, RE (2000) Mycophenolate in the prevention of recurrent neutralizing botulinum toxin A antibodies in cervical dystonia. Mov Disord 15:365–366.Google Scholar

Frevert, J, Dressler, D (2010) Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics 4:325–332.Google Scholar

Gonnering, RS (1988) Negative antibody response to long-term treatment of facial spasm with botulinum toxin. Am J Ophthalmol 105:313–315.Google Scholar

Greene, PE, Fahn, S (1993) Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov Disord 8:479–483.Google Scholar

Greene, P, Fahn, S, Diamond, B (1994) Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 9:213–217.Google Scholar

Hanna, PA, Jankovic, J (1998) Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 50:1624–1629.Google Scholar

Jankovic, J, Schwartz, K (1995) Response and immunoresistance to botulinum toxin injections. Neurology 45:1743–1746.Google Scholar

Kessler, KR, Benecke, R (1997) The EBD test: a clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord 12:95–99.Google Scholar

Naumann, M, Toyka, KV, Mansouri Taleghani, B, Ahmadpour, J, Reiners, K, Bigalke, H (1998) Depletion of neutralising antibodies resensitises a secondary non-responder to botulinum A neurotoxin. J Neurol Neurosurg Psychiat 65:924–927.Google Scholar

Rossetto, O, Pirazzini, M, Montecucco, C (2014) Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol 12:535–549.Google Scholar

Voller, B, Moraru, E, Auff, E, Benesch, M, Poewe, W, Wissel, J, Müller, J, Entner, T, Bigalke, H, Schnider, P (2004) Ninhydrin sweat test: a simple method for detecting antibodies neutralizing botulinum toxin type A. Mov Disord 19:943–947.Google Scholar

References

Anderson, J, Williams, PT, Katos, AM, et al. 2009. Botulinum toxins. In Gupta, RC, ed., Handbook of Toxicology of Chemical Warfare Agents. Amsterdam: Elsevier BV: 407–432.Google Scholar

Chen, R, Karp, BI, Hallett, M. 1998. Botulinum toxin type F for treatment of dystonia: long-term experience. Neurology 51:1494–1496.CrossRef Google Scholar PubMed

Coffield, JA, Bakry, N, Zhang, RD, et al. 1997. In vitro characterization of botulinum toxin types A, C and D action on human tissues: combined electrophysiologic, pharmacologic and molecular biologic approaches. J Pharmacol Exp Ther 280:1489–1498.Google Scholar

Eleopra, R, Tugnoli, V, Rossetto, O, et al. 1997. Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci Lett 224: 91–94.Google Scholar

Eleopra, R, Tugnoli, V, Rossetto, O, et al. 1998. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 256: 135–138.Google Scholar

Eleopra, R, Tugnoli, V, Quatrale, R, et al. 2002. Botulinum neurotoxin serotypes A and C do not affect motor units survival in humans: an electrophysiological study by motor units counting. Clin Neurophysiol 113: 1258–1264.Google Scholar

Eleopra, R, Tugnoli, V, Quatrale, R, et al. 2004. Different types of botulinum toxin in humans. Mov Disord 19 (Suppl. 8):S53–S59.Google Scholar

Eleopra, R, Tugnoli, V, Quatrale, R, et al. 2006. Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F. Neurotox Res 9:127–131.Google Scholar

Eleopra, R, Montecucco, C, Devigili, G, et al. 2013. Botulinum neurotoxin serotype D is poorly effective in humans: an in vivo electrophysiological study. Clin Neurophysiol 124: 999–1004.Google Scholar

Greene, PE, Fahn, S. 1993. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov Disord 8:479–483.Google Scholar

Greene, PE, Fahn, S. 1996. Response to botulinum toxin F in seronegative botulinum toxin A-resistant patients. Mov Disord 11:181–184.Google Scholar

Hallett, M. 2000. How does botulinum toxin work? Ann Neurol 48:7–8.Google Scholar

Jankovic, J. 2004. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiat 75:951–957.Google Scholar

Johnson, EA, Montecucco, C. 2008. Botulism. In: Engel, AG, ed., Neuromuscular Junction Disorders: Handbook of Clinical Neurology. Amsterdam: Elsevier: 333–368.Google Scholar

Ludlow, CL, Hallett, M, Rhew, K, et al. 1992. Therapeutic use of type F botulinum toxin. N Engl J Med 326:349–350.Google Scholar

Mezaki, T, Kaji, R, Brin, MF, et al. 1999. Combined use of type A and F botulinum toxins for blepharospasm: a double-blind controlled trial. Mov Disord 14:1017–1020.Google Scholar

Rossetto, O, Pirazzini, M, Montecucco, C. 2014. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nature 12:535–549.Google Scholar

Smith, LD, Sugiyama, H. 1988. Botulism: The Organism, its Toxins, the Disease. Springfield, IL: C.C. Thomas Publ.Google Scholar

References

Berweck, S, Feldkamp, A, Francke, A, Nehles, J, Schwerin, A, Heinen, F (2002) Sonography-guided injection of botulinum toxin A in children with cerebral palsy. Neuropediatrics 33:221–223.Google Scholar

Boon, AJ, Oney-Marlow, TM, Murthy, NS, Harper, CM, McNamara, TR, Smith, J (2011) Accuracy of electromyography needle placement in cadavers: non-guided vs. ultrasound guided. Muscle Nerve 44:45–49.Google Scholar

Fujimoto, H, Mezaki, T, Yokoe, M, Mochizuki, H (2012) Sonographic guidance provides a low-risk approach to the longus colli muscle. Mov Disord 27:928–929.Google Scholar

Gervasio, A, Mujahed, I, Biasio, A, Alessi, S (2010) Ultrasound anatomy of the neck: the infrahyoid region. J Ultrasound 13:85–89.Google Scholar

Hobson-Webb, LD, Boon, AJ (2013) Reporting the results of diagnostic neuromuscular ultrasound: an educational report. Muscle Nerve 47:608–610.Google Scholar

Hong, JS, Sathe, GG, Niyonkuru, C, Munin, MC (2012) Elimination of dysphagia using ultrasound guidance for botulinum toxin injections in cervical dystonia. Muscle Nerve 46:535–539.Google Scholar

Huang, L, Chen, HX, Ding, XD, Xiao, HQ, Wang, W, Wang, H (2015) Efficacy analysis of ultrasound-guided local injection of botulinum toxin type A treatment with orthopedic joint brace in patients with cervical dystonia. Eur Rev Med Pharmacol Sci 19:1989–1993.Google Scholar

Kopf, H, Mostbeck, GH, Loizides, A, Gruber, H (2011) Ultrasound-guided interventions at peripheral nerves: diagnostic and therapeutic indications. Ultraschall Med 32:440–456.Google Scholar

Lee, IH, Yoon, YC, Sung, DH, Kwon, JW, Jung, JY (2009) Initial experience with imaging-guided intramuscular botulinum toxin injection in patients with idiopathic cervical dystonia. AJR Am J Roentgenol 192:996–1001.Google Scholar

Lim, EC, Quek, AM, Seet, RC (2011) Accurate targeting of botulinum toxin injections: how to and why. Parkinsonism Relat Disord 17 (Suppl. 1):S34–39.Google Scholar

Mezaki, T, Matsumoto, S, Sakamoto, T, Mizutani, K, Kaji, R (2000) Cervical echomyography in cervical dystonia and its application to the monitoring for muscle afferent block (MAB). Rinsho Shinkeigaku 40:689–693.Google Scholar

Peetrons, P (2002) Ultrasound of muscles. Eur Radiol 12:35–43.Google Scholar

Picelli, A, Tamburin, S, Bonetti, P, Fontana, C, Barausse, M, Dambruoso, F, Gajofatto, F, Santilli, V, Smania, N (2012) Botulinum toxin type A injection into the gastrocnemius muscle for spastic equinus in adults with stroke: a randomized controlled trial comparing manual needle placement, electrical stimulation and ultrasonography-guided injection techniques. Am J Phys Med Rehabil 91:957–964.CrossRef Google Scholar PubMed

Picelli, A, Lobba, D, Midiri, A, Prandi, P, Melotti, C, Baldessarelli, S, Smania, N (2014) Botulinum toxin injection into the forearm muscles for wrist and fingers spastic overactivity in adults with chronic stroke: a randomized controlled trial comparing three injection techniques. Clin Rehabil 28:232–242.Google Scholar

Schramm, A, Bäumer, T, Fietzek, U, Heitmann, S, Walter, U, Jost, WH (2015) Relevance of sonography for botulinum toxin treatment of cervical dystonia: an expert statement. J Neural Transm 122:1457–1463.Google Scholar

Walter, U, Dressler, D (2014) Ultrasound-guided botulinum toxin injections in neurology: technique, indications and future perspectives. Expert Rev Neurother 14:923–936.CrossRef Google Scholar PubMed

References

Dressler, D, Adib Saberi, F (2017) Immunological safety of incobotulinumtoxinA (Xeomin^®) therapy with reduced interinjection intervals. J Neural Transm 124:437–440.Google Scholar

Dressler, D, Tacik, P. Adib Saberi, F (2014a) Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects. J Neural Transm 122:297–300.Google Scholar

Dressler, D, Adib Saberi, F, Kollewe, K, Schrader, C (2014b) Safety aspects of incobotulinumtoxinA high dose therapy. J Neural Transm 122:327–333.Google Scholar

References

Albanese, A, Abbruzzese, G, Dressler, D, Duzynski, W, Khatkova, S, Marti, MJ, Mir, P, Montecucco, C, Moro, E, Pinter, M, Relja, M, Roze, E, Skogseid, IM, Timerbaeva, S, Tzoulis, C (2015). Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J Neurol 262:2201–2213.Google Scholar

Baizabal-Carvallo, JF, Jankovic, J, Pappert, E (2011). Flu-like symptoms following botulinum toxin therapy. Toxicon 58:1–7.Google Scholar

Baizabal-Carvallo, JF, Jankovic, J, Feld, J (2013). Flu-like symptoms and associated immunological response following therapy with botulinum toxins. Neurotox Res 2:298–306.Google Scholar

Benecke, R, Jost, WH, Kanovsky, P, Ruzicka, E, Comes, G, Grafe, S (2005). A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64:1949–1951.CrossRef Google Scholar PubMed

Bhidayasiri, R (2011). Treatment of complex cervical dystonia with botulinum toxin: involvement of deep-cervical muscles may contribute to suboptimal responses. Parkinsonism Relat Disord 17 (Suppl. 1):S20–S24.Google Scholar

Brashear, A, Lew, MF, Dykstra, DD, Comella, CL, Factor, SA, Rodnitzky, RL, Trosch, R, Singer, C, Brin, MF, Murray, JJ, Wallace, JD, Willmer-Hulme, A, Koller, M (1999). Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 53:1439–1446.Google Scholar

Brin, MF, Lew, MF, Adler, CH, Comella, CL, Factor, SA, Jankovic, J, O’Brien, C, Murray, JJ, Wallace, JD, Willmer-Hulme, A, Koller, M (1999). Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53:1431–1438.Google Scholar

Brin, MF, Comella, CL, Jankovic, J, Lai, F, Naumann, M; CD-017 BoNTA Study Group (2008). Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23:1353–1360.Google Scholar

Burke, RE, Fahn, S, Marsden, CD (1986). Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 36:160–164.Google Scholar

Charles, D, Brashear, A, Hauser, RA, Li, HI, Boo, LM, Brin, MF; CD 140 Study Group (2012). Efficacy, tolerability, and immunogenicity of onabotulinumtoxinA in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol 35:208–214.Google Scholar

Charles, PD, Adler, CH, Stacy, M, Comella, C, Jankovic, J, Manack Adams, A, Schwartz, M, Brin, MF (2014). Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol 261:1309–1319.Google Scholar

Comella, CL, Jankovic, J, Shannon, KM, Tsui, J, Swenson, M, Leurgans, S, Fan, W; Dystonia Study Group (2005). Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 65:1423–1429.Google Scholar

Comella, CL, Jankovic, J, Truong, DD, Hanschmann, A, Grafe, S; US XEOMIN Cervical Dystonia Study Group (2011). Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 308:103–109.Google Scholar

Comella, CL, Perlmutter, JS, Jinnah, HA, Waliczek, TA, Rosen, AR, Galpern, WR, Adler, CA, Barbano, RL, Factor, SA, Goetz, CG, Jankovic, J, Reich, SG, Rodriguez, RL, Severt, WL, Zurowski, M, Fox, SH, Stebbins, GT (2016). Clinimetric testing of the Comprehensive Cervical Dystonia Rating Scale (CCDRS). Mov Disord 31:563–569.Google Scholar

Defazio, G, Jankovic, J, Giel, JL, Papapetropoulos, S (2013). Descriptive epidemiology of cervical dystonia. Tremor Other Hyperkinet Mov (NY) 4:3.Google Scholar

Dressler, D (2000). Electromyographic evaluation of cervical dystonia for planning of botulinum toxin therapy. Eur J Neurol 7:713–718.Google Scholar

Dressler, D, Benecke, R (2003). Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 49:34–38.Google Scholar

Dressler, D, Bigalke, H (2004). Antibody-induced failure of botulinum toxin type B therapy in de novo patients. Eur Neurol 52:132–135.Google Scholar

Dressler, D, Tacik, P, Saberi, FA (2015). Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects. J Neural Transm 122:297–300.Google Scholar

Evidente, VG, Truong, D, Jankovic, J (2014). IncobotulinumtoxinA (Xeomin(R)) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. J Neurol Sci 346:116–120.Google Scholar

Finsterer, J, Maeztu, C, Revuelta, G, Reichel, G, Truong, D (2015). Collum-caput (COL-CAP) concept for conceptual anterocollis, anterocaput, and forward sagittal shift. J Neurol Sci 355:37–43.Google Scholar

Greene, P, Kang, U, Fahn, S, Brin, M, Moskowitz, C, Flaster, E. (1990). Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 40:1213–1218.CrossRef Google Scholar PubMed

Hallett, M, Albanese, A, Dressler, D, Segal, KR, Simpson, DM, Truong, D, Jankovic, J (2013). Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 67:94–114.Google Scholar

Hanna, PA, Jankovic, J (1998). Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 50:1624–1629.Google Scholar

Jankovic, J (2017). Botulinum toxin: state of the art. Mov Disod 32:1131–1138.Google Scholar

Jankovic, J (2018). An update on new and unique uses of botulinum toxin in movement disorders. Toxicon. Epub ahead of print.Google Scholar

Jankovic, J, Hunter, C, Dolimbek, BZ, Dolimbek, GS, Adler, CH, Brashear, A, Comella, CL, Gordon, M, Riley, DE, Sethi, K, Singer, C, Stacy, M, Tarsy, D, Atassi, MZ (2006). Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 67:2233–2235.Google Scholar

Jankovic, J, Adler, CH, Charles, D, Comella, C, Stacy, M, Schwartz, M, Manack Adams, A, Brin, MF (2015). Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE). J Neurol Sci 349:84–93.Google Scholar

Jindal, P, Jankovic, J (2017). Botulinum toxin treatment in Parkinson’s disease and atypical parkinsonian disorders. In Jabbari, Bahman (ed.) Botulinum Toxin Treatment. New York: Springer.Google Scholar

Jinnah, HA, Goodmann, E, Rosen, AR, Evatt, M, Freeman, A, Factor, S (2016). Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes. J Neurol 263:1188–1194.Google Scholar

Jost, WH, Benecke, R, Hauschke, D, Jankovic, J, Kaňovský, P, Roggenkämper, P, Simpson, DM, Comella, CL (2014). Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Des Devel Ther 9:1913–1926.Google Scholar

Kilbane, C, Ostrem, J, Galifianakis, N, Grace, J, Markun, L, Glass, GA (2012). Multichannel electromyographic mapping to optimize onabotulinumtoxinA efficacy in cervical dystonia. Tremor Other Hyperkinet Mov (NY) 2.Google Scholar

Lew, MF, Adornato, BT, Duane, DD, Dykstra, DD, Factor, SA, Massey, JM, Brin, MF, Jankovic, J, Rodnitzky, RL, Singer, C, Swenson, MR, Tarsy, D, Murray, JJ, Koller, M, Wallace, JD (1997). Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 49:701–707.Google Scholar

Misra, VP, Ehler, E, Zakine, B, Maisonobe, P, Simonetta-Moreau, M; Interest in CD Group (2012). Factors influencing response to botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study. BMJ Open 14(2).Google Scholar

Mordin, M, Masaquel, C, Abbott, C, Copley-Merriman, C (2014). Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled study. BMJ Open 4:e005150.Google Scholar

Nijmeijer, SW, Koelman, JH, Kamphuis, DJ, Tijssen, MA (2012). Muscle selection for treatment of cervical dystonia with botulinum toxin: a systematic review. Parkinsonism Relat Disord 18:731–736.Google Scholar

Odergren, T, Hjaltason, H, Kaakkola, S, Solders, G, Hanko, J, Fehling, C, Marttila, RJ, Lundh, H, Gedin, S, Westergren, I, Richardson, A, Dott, C, Cohen, H (1998). A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 64:6–12.Google Scholar

Pappert, EJ, Germanson, T; Myobloc/Neurobloc European Cervical Dystonia Study (2008). Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord 23: 510–517.Google Scholar

Patel, N, Hanfelt, J, Marsh, L, Jankovic, J; Members of the Dystonia Coalition (2014). Alleviating manoeuvres (sensory tricks) in cervical dystonia. J Neurol Neurosurg Psychiatry 85(8): 882–884.Google Scholar

Poewe, W, Deuschl, G, Nebe, A, Feifel, E, Wissel, J, Benecke, R, Kessler, KR, Ceballos-Baumann, AO, Ohly, A, Oertel, W, Künig, G; German Dystonia Study Group (1998). What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. J Neurol Neurosurg Psychiatry 64:13–17.Google Scholar

Ramirez-Castaneda, J, Jankovic, J (2014). Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon 90:344–348.Google Scholar

Ramirez-Castaneda, J, Jankovic, J, Comella, C, Dashtipour, K, Fernandez, HH, Mari, Z (2013). Diffusion, spread, and migration of botulinum toxin. Mov Disord 28:1775–1783.Google Scholar

Sankhla, C, Jankovic, J, Duane, D (1998). Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord 13:150–154.Google Scholar

Schramm, A, Baumer, T, Fietzek, U, Heitmann, S, Walter, U, Jost, WH (2015). Relevance of sonography for botulinum toxin treatment of cervical dystonia: an expert statement. J Neural Transm 122:1457–1463.Google Scholar

Sethi, KD, Rodriguez, R, Olayinka, B (2012). Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ 15:419–423.Google Scholar

Simpson, DM, Blitzer, A, Brashear, A, Comella, C, Dubinsky, R, Hallett, M, Jankovic, J, Karp, B, Ludlow, CL, Miyasaki, JM, Naumann, M, So, Y; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (2008). Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review) – report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70:1699–1706.Google Scholar

Simpson, DM, Hallet, M, Ashman, EJ, Cornella, CL, Green, MW, Gronseth, GS, Armstrong, MJ, Gloss, D, Potrebic, S, Jankovic, J, Karp, BP, Naumann, M, So, YT, Yablon, SA (2016). Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Report of the Guidelines Development Subcommittee of the American Academy of Neurology. Neurology 86(19): 1818–1826.Google Scholar

Thenganatt, MA, Fahn, S (2012). Botulinum toxin for the treatment of movement disorders. Curr Neurol Neurosci Rep 12:399–409.Google Scholar

Thenganatt, MA, Jankovic, J (2014). Treatment of dystonia. Neurotherapeutics 11: 139–152.Google Scholar

Truong, D, Duane, DD, Jankovic, J, Singer, C, Seeberger, LC, Comella, CL, Lew, MF, Rodnitzky, RL, Danisi, FO, Sutton, JP, Charles, PD, Hauser, RA, Sheean, GL (2005). Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 20:783–791.Google Scholar

Truong, D, Brodsky, M, Lew, M, Brashear, A, Jankovic, J, Molho, E, Orlova, O, Timerbaeva, S; Global Dysport Cervical Dystonia Study Group (2010). Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 16:316–323.Google Scholar

Wu, C, Xue, F, Chang, W, Lian, Y, Zheng, Y, Xie, N, Zhang, L, Chen, C (2016). Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia. Springerplus 8 (5):1292.Google Scholar

Yun, JY, Kim, JW, Kim, HT, Chung, SJ, Kim, JM, Cho, JW, Lee, JY, Lee, HN, You, S, Oh, E, Jeong, H, Kim, YE, Kim, HJ, Lee, WY, Jeon, BS (2015). Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study. Mov Disord 30:206–213.Google Scholar

References

Albanese, A, Asmus, F, Bhatia, KP, Elia, AE, Elibol, B, Filippini, G, Gasser, T, Krauss, JK, Nardocci, N, Newton, A, Valls-Solé, J (2011). EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 18:5–18.Google Scholar

Aramideh, M, Bour, LJ, Koelman, JH, Speelman, JD, Ongerboer de Visser, BW (1994). Abnormal eye movements in blepharospasm and involuntary levator palpebrae inhibition: clinical and pathophysiological considerations. Brain 117:1457–1474.Google Scholar

Brin, M, Danisio, F, Blitzer, A (2003). Blephaospasm, oromandibular dystonia, Meige’s syndrome and hemifacial spasm. In: Moore, AP, Naumann, M (eds) Handbook of Botulinum Toxin Treatment. Oxford: Blackwell Scientific.Google Scholar

Colosimo, C, Chianese, M, Contarino, F, Giovannelli, M, Bentivoglio, AR (2003). Botulinum toxin type B in blepharospasm and hemifacial spasm. J Neurol, Neurosurg Psychiatry 74:687.Google Scholar

Colosimo, C, Suppa, A, Fabbrini, G, Bologna, M, Berardelli, A (2010). Craniocervical dystonia: clinical and pathophysiological features. Eur J Neurol 17 (Suppl. 1):15–21.Google Scholar

Colosimo, C, Tiple, D, Berardelli, A (2012). Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox Res 22:265–273.Google Scholar

Defazio, G, Matarin, M, Peckham, EL, Peckham, EL, Martino, D, Valente, EM, Singleton, A, Crawley, A, Aniello, MS, Brancati, F, Abbruzzese, G, Girlanda, P, Livrea, P, Hallett, M, Berardelli, A (2009). The TOR1A polymorphism rs1182 and the risk of spread in primary blepharospasm. Mov Disord 24(4):613–616.Google Scholar

Girlanda, P, Quartarone, A, Sinicropi, S, Nicolosi, C, Messina, C (1996). Unilateral injection of botulinum toxin in blepharospasm: single fiber electromyography and blink reflex study. Mov Disord 11:27–31.Google Scholar

Goldstein, JE, Cogan, DG (1965). Apraxia of lid opening. Arch Ophthalmol 73:155–159.Google Scholar

Gonzalez-Alegre, P, Schneider, RL, Hoffman, H (2014). Clinical, etiological, and therapeutic features of jaw-opening and jaw-closing oromandibular dystonias: a decade of experience at a single treatment center. Tremor Other Hyperkinet Mov (NY) 30(4):231.Google Scholar

Grandas, F, Elston, J, Quinn, N, Marsden, CD (1988). Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry 51:767–772.Google Scholar

Hellman, A, Torres-Russotto, D (2015). Botulinum toxin in the management of blepharospasm: current evidence and recent developments. Ther Adv Neurol Disord 8(2):82–91.Google Scholar

Jankovic, J, Ford, J (1983). Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol 13:402–411.Google Scholar

Jankovic, J, Orman, J (1987). Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 37:616–623.Google Scholar

Jankovic, J, Comella, C, Hanschmann, A, Grafe, S (2011). Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm: a randomized trial. Mov Disord 26:1521–1528.Google Scholar

Kraft, SP, Lang, AE (1988). Cranial dystonia, blepharospasm and hemifacial spasm: clinical features and treatment, including the use of botulinum toxin. CMAJ 139:837–844.Google Scholar

Lee, SJ, McCall, WD Jr, Kim, YK (2010). Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial. Am J Phys Med Rehabil 89:16–23.Google Scholar

Meige, H (1910). Les convulsions de la face: une forme clinique de convulsions faciales, bilaterales et mediane. Rev Neurol (Paris) 21:437–443.Google Scholar

Mendes, RA, Upton, LG (2009). Management of dystonia of the lateral pterygoid muscle with botulinum toxin A. Br J Oral Maxillofac Surg 47:481–483.Google Scholar

Nuessgens, Z, Roggenkamper, P (1997). Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmo 235:197–199.Google Scholar

Ramirez-Castaneda, J, Jankovic, J (2013). Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins 5:249–266.Google Scholar

Roggenkamper, P, Jost, WH, Bihari, K, Comes, G, Grafe, S; NT 201 Blepharospasm Study Team (2006). Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 113:303–312.Google Scholar

Schneider, SA, Aggarwal, A, Bhatt, M, Dupont, E, Tisch, S, Limousin, P, Lee, P, Quinn, N, Bhatia, KP (2006). Severe tongue protrusion dystonia: clinical syndromes and possible treatment. Neurology 26(67):940–943.Google Scholar

Scott, AB, Rosenbaum, A, Collins, CC (1973). Pharmacologic weakening of extraocular muscles. Invest Ophthalmol Vis Sci 12:924–927.Google Scholar

Tan, EK, Jankovic, J (1999). Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 53:2102–2107.Google Scholar

Thompson, PD, Obeso, JA, Delgado, G, Gallego, J, Marsden, CD (1986). Focal dystonia of the jaw and the differential diagnosis of unilateral jaw and masticatory spasm. J Neurol Neurosurg Psychiatry 49:651–656.Google Scholar

Truong, D, Comella, C, Fernandez, HH, Ondo, WG; Dysport Benign Essential Blepharospasm Study Group (2008). Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord 14:407–414.Google Scholar

Wabbels, B, Reichel, G, Fulford-Smith, A, Wright, N, Roggenkämper, P (2011). Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm 11:233–239.Google Scholar

Weiss, EM, Hershey, T, Karimi, M, Racette, B, Tabbal, SD, Mink, JW, Paniello, RC, Perlmutter, JS (2006). Relative risk of spread of symptoms among the focal onset primary dystonias. Mov Disord 21:1175–1181.Google Scholar

References

Adler, CH, Bansberg, SF, Krein-Jones, K, Hentz, JG. 2004. Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia. Mov Disord 19(9): 1075–1079.Google Scholar

Aronson, AE, De Santo, LW. 1983. Adductor spastic dysphonia: three years after recurrent laryngeal nerve resection. Laryngoscope 93(1): 1–8.Google Scholar

Aronson, AE, Lagerlund, TD. 1991. Neuroimaging studies do not prove the existence of brain abnormalities in spastic (spasmodic) dysphonia. J Speech Hear Res 34(4): 801–811.Google Scholar

Aronson, AE, Brown, JR, Litin, EM, Pearson, JS. 1968. Spastic dysphonia: I. Voice, neurologic, and psychiatric aspects. J Speech Hear Disord 33(3): 203–218.Google Scholar

Atassi, MZ. 2004. Basic immunological aspects of botulinum toxin therapy. Mov Disord 19(Suppl. 8): S68–S84.Google Scholar

Atassi, MZ. 2009. Immune recognition of BoNTs A and B: how anti-toxin antibodies that bind to the heavy chain obstruct toxin action. Toxicon 54(5):600–613.Google Scholar

Atassi, MS, Dolimbek, BZ, Jankovic, J, Steward, LE, Aoki, KR. 2011. Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment: the antigenic structure of the active toxin recognized by human antibodies. Immunobiology 216(7):782–792.Google Scholar

Berke, GS, Blackwell, KE, Gerratt, BR, Verneil, A, Jackson, KS, Sercarz, JA. 1999. Selective laryngeal adductor denervation-reinnervation: a new surgical treatment for adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 108(3): 227–231.Google Scholar

Bielamowicz, S, Stager, SV, Badillo, A. Godlewski, A. 2002. Unilateral versus bilateral injections of botulinum toxin in patients with adductor spasmodic dysphonia. J Voice 16(1): 117–123.Google Scholar

Blitzer, A. 2005. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia. Otolaryngol Head Neck Surg 133(6): 836–838.Google Scholar

Blitzer, A, Lovelace, RE, Brin, MF, Fahn, S, Fink, ME. 1985. Electromyographic findings in focal laryngeal dystonia (spastic dysphonia). Ann Otol Rhinol Laryngol 94(6 Pt 1): 591–594.Google Scholar

Blitzer, A, Brin, MF, Stewart, CF. 1998. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 108(10): 1435–1441.Google Scholar

Carlsoo, B, Izdebski, K, Dahlqvist, A, Domeij, S, Dedo, HH. 1987. The recurrent laryngeal nerve in spastic dysphonia: a light and electron microscopic study. Acta Otolaryngol 103(1–2): 96–104.Google Scholar

Chhetri, DK, Blumin, JH, Vinters, HV, Berke, GS. 2003. Histology of nerves and muscles in adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 112(4): 334–341.Google Scholar

Critchley, M. 1939. Spastic dysphonia ‘inspiratory speech’. Brain 62: 96–103.Google Scholar

Dedo, HH. 1976. Recurrent laryngeal nerve section for spastic dysphonia. Ann Otol Rhinol Laryngol 85(4 Pt 1): 451–459.Google Scholar

Dedo, HH, Izdebski, K. 1984. Evaluation and treatment of recurrent spasticity after recurrent laryngeal nerve section: a preliminary report. Ann Otol Rhinol Laryngol 93(4 Pt 1): 343–345.Google Scholar

Feldman, M, Nixon, JV, Finitzo-Hieber, T, Freeman, FJ. 1984. Abnormal parasympathetic vagal function in patients with spasmodic dysphonia. Ann Intern Med 100(4): 491–495.Google Scholar

Finitzo-Hieber, T, Freeman, FJ, Gerling, IJ, Dobson, L, Schaefer, SD. 1982. Auditory brainstem response abnormalities in adductor spasmodic dysphonia. Am J Otolaryngol 3(1): 26–30.Google Scholar

Hillel, AD, Maronian, NC, Waugh, PF, Robinson, L, Klotz, DA. 2004. Treatment of the interarytenoid muscle with botulinum toxin for laryngeal dystonia. Ann Otol Rhinol Laryngol 113(5): 341–348.Google Scholar

Isshiki, N, Yamamoto, I, Fukagai, S. 2004. Type 2 thyroplasty for spasmodic dysphonia: fixation using a titanium bridge. Acta Otolaryngol 124(3): 309–312.Google Scholar

Jacome, DE, Yanez, GF. 1980. Spastic dysphonia and Meigs disease. Neurology 30(4): 349.Google Scholar

Marsden, CD, Sheehy, MP. 1982. Spastic dysphonia, Meige disease, and torsion dystonia. Neurology 32(10): 1202–1203.Google Scholar

Meyer, T, Blitzer, A. 2006. Spasmodic dysphonia. In: Stacy, M, ed. Handbook of Dystonia. London: CRC Press, pp. 179–188.Google Scholar

Murry, T, Woodson, GE. 1995. Combined-modality treatment of adductor spasmodic dysphonia with botulinum toxin and voice therapy. J Voice 9(4): 460–465.Google Scholar

Netterville, JL, Stone, RE, Rainey, C, Zealear, DL, Ossoff, RH. 1991. Recurrent laryngeal nerve avulsion for treatment of spastic dysphonia. Ann Otol Rhinol Laryngol 100(1): 10–14.Google Scholar

Newton-John, H. 1988. Acute upper airway obstruction due to supraglottic dystonia induced by a neuroleptic. BMJ 297(6654): 964–965.Google Scholar

N‘ovakovic, D, Waters, HH, D'Elia, JB, Blitzer, A. 2011. Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes. Laryngoscope 121(3): 606–612.Google Scholar

Ravits, JM, Aronson, AE, DeSanto, LW, Dyck, PJ. 1979. No morphometric abnormality recurrent laryngeal nerve in spastic dysphonia. Neurology 29(10): 1376–1382.Google Scholar

Roark, RM, Dowling, EM, DeGroat, RD, Watson, BC, Schaefer, SD. 1995. Time-frequency analyses of thyroarytenoid myoelectric activity in normal and spasmodic dysphonia subjects. J Speech Hear Res 38(2): 289–303.Google Scholar

Sapienza, CM, Walton, S, Murry, T. 2000. Adductor spasmodic dysphonia and muscular tension dysphonia: acoustic analysis of sustained phonation and reading. J Voice 14(4): 502–520.Google Scholar

Schaefer, SD. 1983. Neuropathology of spasmodic dysphonia. Laryngoscope 93(9): 1183–1204.Google Scholar

Schaefer, S, Freeman, F, Finitzo, T, Close, L, Cannito, M, Ross, E, Reisch, J, Maravilla, K. 1985. Magnetic resonance imaging findings and correlations in spasmodic dysphonia patients. Ann Otol Rhinol Laryngol 94(6 Pt 1): 595–601.Google Scholar

Schaefer, SD, Finitzo-Hieber, T, Gerling, IJ, Freeman, FJ. 1983. Brainstem conduction abnormalities in spasmodic dysphonia. Ann Otol Rhinol Laryngol 92(1 Pt 1): 59–64.Google Scholar

Traube, L. 1871. Zur Lehre von den Larynxaffectionen beim Ileotyphus. Berlin: Verlag Van August Hisschwald, pp. 674–678.Google Scholar

Tucker, HM. 1989. Laryngeal framework surgery in the management of spasmodic dysphonia: preliminary report. Ann Otol Rhinol Laryngol. 98(1 Pt 1): 52–54.Google Scholar

Van Pelt, F, Ludlow, CL, Smith, PJ. 1994. Comparison of muscle activation patterns in adductor and abductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 103(3): 192–200.Google Scholar

Warren, J, Thompson, P. 1998. Drug-induced supraglottic dystonia and spasmodic dysphonia. Mov Disord 13(6): 978–979.Google Scholar

Weed, DT, Jewett, BS, Rainey, C, Zealear, DL, Stone, RE, Ossoff, RH, Netterville, JL. 1996. Long-term follow-up of recurrent laryngeal nerve avulsion for the treatment of spastic dysphonia. Ann Otol Rhinol Laryngol 105(8): 592–601.Google Scholar

References

Asahi, T, Koh, M, Kashiwazaki, D, Kuroda, S. 2014. Stereotactic neurosurgery for writer’s cramp: report of two cases with an overview of the literature. Stereotact Funct Neurosurg 92:405–411.Google Scholar

Cohen, LG, Hallett, M. 1988. Hand cramps: clinical features and electromyographic patterns in a focal dystonia. Neurology 38:1005–1012.Google Scholar

Epidemiological Study of Dystonia in Europe Collaborative Group. 2000. A prevalence study of primary dystonia in eight European countries. J Neurol 247:787–792.Google Scholar

Grigoriu, AI, Dinomais, M, Remy-Neris, O, Brochard, S. 2015. Impact of injection-guiding techniques on the effectiveness of botulinum toxin for the treatment of focal spasticity and dystonia: a systematic review. Arch Phys Med Rehabil 96:2067–2078.Google Scholar

Hallett, M, Albanese, A, Dressler, D, Segal, KR, Simpson, DM, Truong, D, Jankovic, J. 2013. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 67:94–114.Google Scholar

Jankovic, J, Van der Linden, C. 1988. Dystonia and tremor induced by peripheral trauma: predisposing factors. J Neurol Neurosurg Psychiatry 51:1512–1519.Google Scholar

Jost, W, Valerius, K-P 2008. Pictorial Atlas of Botulinum Toxin Injection: Dosage, Localization, Application. Berlin: KVM.Google Scholar

Karp, BI. 2012. Botulinum toxin physiology in focal hand and cranial dystonia. Toxins 4:1404–1414.Google Scholar

Karp, BI, Cole, RA, Cohen, LG, Grill, S, Lou, JS, Hallett, M. 1994. Long-term botulinum toxin treatment of focal hand dystonia. Neurology 44:70–76.Google Scholar

Kruisdijk, JJ, Koelman, JH, Ongerboer de Visser, BW, de Haan, RJ, Speelman, JD. 2007. Botulinum toxin for writer’s cramp: a randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry 78:264–270.Google Scholar

Lungu, C, Karp, BI, Alter, K, Zolbrod, R, Hallett, M. 2011. Long-term follow-up of botulinum toxin therapy for focal hand dystonia: outcome at 10 years or more. Mov Disord 26:750–753.Google Scholar

Molloy, FM, Shill, HA, Kaelin-Lang, A, Karp, BI. 2002. Accuracy of muscle localization without EMG: implications for treatment of limb dystonia. Neurology 58:805–807.Google Scholar

Nibbeling, E, Schaake, S, Tijssen, MA, Weissbach, A, Groen, JL, Altenmüller, E, Verbeek, DS, Lohmann, K. 2015. Accumulation of rare variants in the arylsulfatase G (ARSG) gene in task-specific dystonia. J Neurol 262:1340–1343.Google Scholar

Nutt, JG, Muenter, MD, Melton, LJ, 3rd, Aronson, A, Kurland, LT. 1988. Epidemiology of dystonia in Rochester, Minnesota. Adv Neurol 50:361–365.Google Scholar

Sheehy, MP, Marsden, CD. 1982. Writers’ cramp: a focal dystonia. Brain 105 (Pt 3):461–480.Google Scholar

Simpson, DM, Blitzer, A, Brashear, A, Comella, C, Dubinsky, R, Hallett, M, Jankovic, J, Karp, B, Ludlow, CL, Miyasaki, JM, Naumann, M, So, Y. 2008. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70:1699–1706.Google Scholar

Truong, D, Hallett, M, Zachary, C, Dressler, D (Eds). 2014. Manual of Botulinum Toxin Therapy, 2nd edn. Cambridge: Cambridge University Press.Google Scholar

Wissel, J, Kabus, C, Wenzel, R, Klepsch, S, Schwarz, U, Nebe, A, Schelosky, L, Scholz, U, Poewe, W. 1996. Botulinum toxin in writer’s cramp: objective response evaluation in 31 patients. J Neurol Neurosurg Psychiatry 61:172–175.Google Scholar

Yoshimura, DM, Aminoff, MJ, Olney, RK. 1992. Botulinum toxin therapy for limb dystonias. Neurology 42:627–630.Google Scholar

References

Carrillo, RJC (2011). Pterygoid botulinum toxin injection. Philipp J Otolaryngol Head Neck Surg 26:55–56.Google Scholar

Ernberg, M, Hedenberg-Magnusson, B, List, T, Svensson, P (2011). Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: a randomized, controlled, double-blind multicenter study. Pain 152:1988–1996.Google Scholar

Frisardi, G, Iani, C, Sau, G, Frisardi, F, Leornadis, C, Lumbau, A, Enrico, P, Sirca, D, Staderini, EM, Chessa, G (2013). A relationship between bruxism and orofacial dystonia? A trigeminal electrophysiological approach in a case report of pineal cavernoma. Behav Brain Funct 9:41.Google Scholar

Gjovreku, E, Vyshka, G (2013). Nocturnal bruxism: still a nosological conundrum? WebmedCentral Dentistry 4(5):WMC004234.Google Scholar

Guarda-Nardini, L, Manfredini, D, Salamone, M, Salmaso, L, Tonello, S, Ferronato, G (2008). Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study. Cranio 26:126–135.Google Scholar

Laine, CM, Yavuz, ŞU, D’Amico, JM, Gorassini, MA, Türker, KS, Farina, D (2015). Jaw tremor as a physiological biomarker of bruxism. Clin Neurophysiol 126:1746–1753.Google Scholar

Lee, SJ, McCall, WD, Kim, YK, Chung, SC, Chung, JW (2010). Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial. Am J Phys Med Rehabil 89:16–23.Google Scholar

Long, H, Liao, Z, Wang, Y, Liao, L, Lai, W (2012). Efficacy of botulinum toxins on bruxism: an evidence-based review. Int Dent J 62:1–5.Google Scholar

Mor, N, Tang, C, Blitzer, A (2015). Temporomandibular myofascial pain treated with botulinum toxin injection. Toxins 7:2791–2800.Google Scholar

Murray, GM, Phanachet, I, Uchida, S, Whittle, T (2001). The role of the human lateral pterygoid muscle in the control of horizontal jaw movements. J Orofac Pain 15: 279–292; discussion 292–305.Google Scholar

Nayyar, P, Kumar, P, Nayyar, PV, Singh, A (2014). Botox: broadening the horizon of dentistry. J Clin Diagn Res 8:ZE25–ZE29.Google Scholar

Onodera, K, Sato, S (2008). Bruxism evaluating sheet. United States Patent Application: 20080211123. www.freepatentsonline.com/y2008/0211123.html (accessed 11 October 2016).Google Scholar

Orlova, O, Soikher, MI, Soikher, MG, Mingazova, L, Kotlyarov, V, Slavicek, G (2010). Therapeutic application of botulinum toxin A in patients with local muscle dystonia and oral dyskinesia. J Stomat Occ Med 3:23–28.Google Scholar

Persaud, R, Garas, G, Silva, S, Stamatoglou, C, Chatrath, P, Patel, K (2013). An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions. JRSM Short Rep 4:10.Google Scholar

Shim, YJ, Lee, MK, Kato, T, Park, HU, Heo, K, Kim, ST (2014). Effects of botulinum toxin on jaw motor events during sleep in sleep bruxism patients: a polysomnographic evaluation. J Clin Sleep Med 10: 291–298.Google Scholar

Sposito, M, Teixeira, S (2014). Botulinum toxin A for bruxism: a systematic review. Acta Fisiatr 21:201–204.Google Scholar

Tintner, R, Jankovic, J (2002). Botulinum toxin type A in the management of oromandibular dystonia and bruxism. In: Brin, MF, Hallett, M, J (Eds), Jankovic. Scientific and Therapeutic Aspects of Botulinum Toxin. Lippincott Williams & Wilkins, Philadelphia, PA.Google Scholar

References

Aramideh, M, Ongerboer de Visser, BW, Devriese, PP, Bour, LJ, Speelman, JD (1994) Electromyographic features of levator palpebrae superioris and orbicularis oculi muscles in blepharospasm. Brain 117:27–38.Google Scholar

Aramideh, M, Ongerboer de Visser, BW, Brans, JW, Koelman, JH, Speelman, JD (1995) Pretarsal application of botulinum toxin for treatment of blepharospasm. J Neurol Neurosurg Psychiatry 59:309–311.Google Scholar

Ben Simon, GJ, Macedo, AA, Schwarcz, RM, Wang, DY, McCann, JD, Goldberg, RA (2005) Frontalis suspension for upper eyelid ptosis: evaluation of different surgical designs and suture materials. Am J Ophthalmol 140:887–885.Google Scholar

Boghen, D, Tozlovanu, V, Iancu, A, Forget, R (2002) Botulinum toxin therapy for apraxia of lid opening. Ann NY Acad Sci 956:482–483.Google Scholar

Dewey, RB Jr, Maraganore, DM (1994) Isolated eyelid opening apraxia: report of a new levodopa-responsive syndrome. Neurology 44:1752–1754.Google Scholar

Dressler, D, Karapantzou, C, Rohrbach, S, Schneider, S, Laskawi, R (2017) Frontalis suspension surgery to treat patients with blepharospasm and eyelid opening apraxia: long-term results. J Neural Transm 124:253–257.Google Scholar

Forget, R, Tozlovanu, V, Iancu, A, Boghen, D (2002) Botulinum toxin improves lid opening delays in blepharospasm-associated apraxia of lid opening. Neurology 58:1843–1846.Google Scholar

Georgescu, D, Vagefi, MR, McMullan, TFW, McCann, JD, Anderson, RL (2008) Upper eyelid myectomy in blepharospasm with associated apraxia of lid opening. Am J Ophthalmol 145:541–547.Google Scholar

Grivet, D, Robert, PY, Thuret, G, De Feligonde, OP, Gain, P, Maugery, J, Adenis, JP (2005) Assessment of blepharospasm surgery using an improved disability scale: study of 138 patients. Ophthal Plast Reconstr Surg 21:230–234.Google Scholar

Hayashi, K, Katori, N, Kasai, K, Kamisasanuki, T, Kokubo, K, Ohno-Matsui, K (2013) Comparison of nylon monofilament suture and polytetrafluoroethylene sheet for frontalis suspension surgery in eyes with congenital ptosis. Am J Ophthalmol 155:654–663.Google Scholar

Jost, W (2007) Bildatlas der Botulinumtoxin-Injektion: Dosierung, Lokalisation, Anwendung. Marburg: KVM.Google Scholar

Karapantzou, C (2013) Blepharospasmus vom Levator-Inhibitions-Typ – Analyse von Patienten nach Lid-Frontalis-Suspensions Operation und Literaturübersicht. Medical Dissertation, Göttingen.Google Scholar

Karapantzou, C, Dressler, D, Rohrbach, S, Laskawi, R (2014) Frontalis suspension surgery to treat patients with essential blepharospasm and apraxia of eyelid opening-technique and results. Head Face Med 10:44.Google Scholar

Kollewe, K, Mohammadi, B, Köhler, S, Pickenbrock, H, Dengler, R, Dressler, D (2015) Blepharospasm: long-term treatment with either Botox^®, Xeomin^® or Dysport^®. J Neural Transm 122:427–431.Google Scholar

Lee, KC, Finley, R, Miller, B (2004) Apraxia of lid opening: dose-dependent response to carbidopa-levodopa. Pharmacotherapy 24:401–403.Google Scholar

Lemagne, JM, Liu, C (1991) Complications of frontalis suspension using polytetrafluoroethylene (Gore-Tex). Orbit 10:29–31.Google Scholar

Marsden, CD (1976) Blepharospasm-oromandibular dystonia syndrome (Brueghel’s syndrome): a variant of adult-onset torsion dystonia? J Neurol Neurosurg Psychiatry 39:1204–1209.Google Scholar

Moss, HL (1982) Prothesis for blepharoptosis and blepharospasm. J Am Optom Assoc 53:661–667.Google Scholar

Nüssgens, Z, Roggenkämper, P (1995) Long-term treatment of blepharospasm with botulinum toxin type A. Ger J Ophthalmol 4:363–367.Google Scholar

Patel, BC, Anderson, RL (1995) Blepharospasm and related facial movement disorders. Curr Opin Ophthalmol 6:86–99.Google Scholar

Patil, B, Foss, AJE (2009) Upper lid orbicularis muscle strip and sequential brow suspension with autologous fascia lata is beneficial for selected patients with essential blepharospasm. Eye 23:1549–1553.Google Scholar

Putterman, AM, Urist, M (1972) Treatment of essential blepharospasm with a frontalis sling. Arch Ophthalmol 88:278–281.Google Scholar

Ramasamy, B, Rowe, F, Freeman, G, Owen, M, Noonan, C (2007) Modified Lundie loops improve apraxia of eye lid opening. J Neuroophthalmol 27:32–35.Google Scholar

Rana, AQ, Shah, R (2012) Combination of blepharospasm and apraxia of eye lid opening: a condition resistant to treatment. Acta Neurol Belg 112:95–96.Google Scholar

Roggenkämper, P, Nüssgens, Z (1993) Frontalis suspension in the treatment of essential blepharospasm unresponsive to botulinum toxin therapy: first results. Ger J Ophthalmol 2: 426–428.Google Scholar

Roggenkämper, P, Nüssgens, Z (1997) Frontalis suspension in the treatment of essential blepharospasm unresponsive to botulinum toxin therapy: long-term results. Graefe’s Arch Clin Exp Ophthalmol 235: 486–489.Google Scholar

Scott, AB, Kennedy, RA, Stubbs, HA (1985) Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol 103:347–350.Google Scholar

Takahashi, Y, Leibovitch, I, Kakzaki, H (2010) Frontalis suspension surgery in upper eyelid blepharoptosis. Open Ophthamol J 4:91–97.Google Scholar

Wabbels, B, Roggenkämper, P (2007) Long-term follow up of patients with frontalis sling operation in the treatment of essential blepharospasm unresponsive to botulinum toxin therapy. Graefe’s Arch Clin Exp Ophthalmol 245: 45–50.Google Scholar

Wasserman, B, Springer, DT, Helveston, EM (2001) Comparison of materials used in frontalis suspension surgery. Arch Ophthalmol 118:687–691.Google Scholar

Yamada, S, Matsuo, K, Hirayama, M, Sobue, G (2005) The effects of levodopa on apraxia of lid opening: a case report. Neurology 62:830–831.Google Scholar

References

Dressler, D, Kupsch, A, Seitzinger, A, Paus, S (2014) The Dystonia Discomfort Scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia. Eur J Neurol 21:459–462.Google Scholar

Moore, P, Naumann, M (2003) General and clinical aspects of treatment with botulinum toxin. In: Moore, P, Naumann, M (eds) Handbook of Botulinum Toxin Treatment, 2nd edition. Blackwell Science, Malden, MA, pp. 68–69.Google Scholar

Book contents

Section II - Botulinum Toxin Therapy

Summary

Access options

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive